Edwards Lifesciences (NYSE:EW) VP Sells $56,762.30 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. The trade was a 1.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $92.22 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a 50-day moving average of $86.73 and a 200-day moving average of $83.85. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company has a market cap of $53.10 billion, a P/E ratio of 49.05, a P/E/G ratio of 2.31 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a research report on Wednesday, April 1st. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Royal Bank Of Canada restated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Finally, Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $97.09.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds have recently bought and sold shares of the company. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $25,000. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $25,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at $26,000. RMG Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the first quarter worth $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter worth $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.